| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
Division of Basic Immunology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206;
Department of Dermatology, University of Colorado Health Sciences Center, Denver, CO 80262;
Department of Comparative Medicine, University of Washington, Seattle, WA 98195;
Megabios Corporation, Burlingame, CA 94010;
¶
Department of Pharmacology, University of Wisconsin, Madison, WI 53706; and
||
Department of Immunology and the Cancer Center, University of Colorado Health Sciences Center, Denver, CO 80262
Cationic lipid-DNA complexes (CLDC) are reported to be safe and
effective for systemic gene delivery, particularly to the lungs.
However, we observed that i.v. injection of CLDC induced immunologic
effects not previously reported. We found that even very low doses of
CLDC administered i.v. induced marked systemic immune activation. This
response included strong up-regulation of CD69 expression on multiple
cell types and systemic release of high levels of Th1 cytokines, from
both lung and spleen mononuclear cells. CLDC were much more potent
immune activators on a per weight basis than either LPS or poly(I:C).
The remarkable potency of CLDC appeared to result from enhancement of
the immune stimulatory properties of DNA, since cationic lipids alone
were without immune stimulatory activity. Systemic treatment with CLDC
controlled tumor growth and significantly prolonged survival times in
mice with metastatic pulmonary tumors. NK cells accumulated to high
levels in the lungs of CLDC-treated mice, were functionally activated,
and released high levels of IFN-
. The antitumor activity induced by
CLDC injection was dependent on both NK cells and IFN-. Thus, DNA
complexed to cationic liposomes becomes highly immunostimulatory
and capable of inducing strong antitumor activity when
administered systemically.
This article has been cited by other articles:
|
|
 |
|
  K. Takeda, S. W. Dow, N. Miyahara, T. Kodama, T. Koya, C. Taube, A. Joetham, J.-W. Park, A. Dakhama, R. M. Kedl, et al. Vaccine-Induced CD8+ T Cell-Dependent Suppression of Airway Hyperresponsiveness and Inflammation J. Immunol., July 1, 2009; 183(1): 181 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Bernstein, R. D. Cardin, F. J. Bravo, J. E. Strasser, N. Farley, C. Chalk, M. Lay, and J. Fairman Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes Vaccines Clin. Vaccine Immunol., May 1, 2009; 16(5): 699 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goodyear, L. Kellihan, H. Bielefeldt-Ohmann, R. Troyer, K. Propst, and S. Dow Protection from Pneumonic Infection with Burkholderia Species by Inhalational Immunotherapy Infect. Immun., April 1, 2009; 77(4): 1579 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhowmick, R. Ravindran, and N. Ali gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with Leishmania donovani Infect. Immun., March 1, 2008; 76(3): 1003 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Gowen, M.-H. Wong, K.-H. Jung, A. B. Sanders, W. M. Mitchell, L. Alexopoulou, R. A. Flavell, and R. W. Sidwell TLR3 Is Essential for the Induction of Protective Immunity against Punta Toro Virus Infection by the Double-Stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): Differential Recognition of Synthetic dsRNA Molecules J. Immunol., April 15, 2007; 178(8): 5200 - 5208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Zaks, M. Jordan, A. Guth, K. Sellins, R. Kedl, A. Izzo, C. Bosio, and S. Dow Efficient Immunization and Cross-Priming by Vaccine Adjuvants Containing TLR3 or TLR9 Agonists Complexed to Cationic Liposomes. J. Immunol., June 15, 2006; 176(12): 7335 - 7345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brignole, F. Pastorino, D. Marimpietri, G. Pagnan, A. Pistorio, T. M. Allen, V. Pistoia, and M. Ponzoni Immune Cell-Mediated Antitumor Activities of GD2-Targeted Liposomal c-myb Antisense Oligonucleotides Containing CpG Motifs J Natl Cancer Inst, August 4, 2004; 96(15): 1171 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Jiao, R. Y.-H. Wang, Q. Qiu, H. J. Alter, and J. W.-K. Shih Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes J. Gen. Virol., June 1, 2004; 85(6): 1545 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, W. J. Gasper, S. A. Stass, O. B. Ioffe, M. A. Davis, and A. J. Mixson Angiogenic Inhibition Mediated by a DNAzyme That Targets Vascular Endothelial Growth Factor Receptor 2 Cancer Res., October 1, 2002; 62(19): 5463 - 5469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Espinoza-Delgado Cancer Vaccines Oncologist, August 1, 2002; 7(90003): 20 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D'Souza, V. Rosseels, O. Denis, A. Tanghe, N. De Smet, F. Jurion, K. Palfliet, N. Castiglioni, A. Vanonckelen, C. Wheeler, et al. Improved Tuberculosis DNA Vaccines by Formulation in Cationic Lipids Infect. Immun., July 1, 2002; 70(7): 3681 - 3688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, H. D. Liggitt, S. Dow, C. Handumrongkul, T. D. Heath, and R. J. Debs Strain-based Genetic Differences Regulate the Efficiency of Systemic Gene Delivery as Well as Expression J. Biol. Chem., February 8, 2002; 277(7): 4966 - 4972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. K. Ballas, A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs J. Immunol., November 1, 2001; 167(9): 4878 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mui, S. G. Raney, S. C. Semple, and M. J. Hope Immune Stimulation by a CpG-Containing Oligodeoxynucleotide Is Enhanced When Encapsulated and Delivered in Lipid Particles J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1185 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, J. Zhang, S. A. Moore, Z. K. Ballas, J. P. Portanova, A. M. Krieg, and D. J. Berg CpG DNA induces cyclooxygenase-2 expression and prostaglandin production Int. Immunol., August 1, 2001; 13(8): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. West and D. M. Rodman Gene Therapy for Pulmonary Diseases Chest, February 1, 2001; 119(2): 613 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lanuti, S. Rudginsky, S. D. Force, E. S. Lambright, W. M. Siders, M. Y. Chang, K. M. Amin, L. R. Kaiser, R. K. Scheule, and S. M. Albelda Cationic Lipid:Bacterial DNA Complexes Elicit Adaptive Cellular Immunity in Murine Intraperitoneal Tumor Models Cancer Res., June 1, 2000; 60(11): 2955 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Albelda, R. Wiewrodt, and J. B. Zuckerman Gene Therapy for Lung Disease: Hype or Hope? Ann Intern Med, April 18, 2000; 132(8): 649 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Horton, O. Dorigo, P. Hernandez, D. Anderson, J. S. Berek, and S. E. Parker IL-2 Plasmid Therapy of Murine Ovarian Carcinoma Inhibits the Growth of Tumor Ascites and Alters Its Cytokine Profile J. Immunol., December 15, 1999; 163(12): 6378 - 6385. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
